Seattle biotech company Stratos Genomics today announced a new partnership with Roche, a Switzerland-based biotech giant.
Roche has made a strategic investment in Stratos to support development of the company’s technology, called Sequencing By Expansion (SBX), which converts DNA into more easily-read polymer and makes it cheaper and faster to sequence DNA.
Roche, a leader in research-focused healthcare that employs more than 80,000 worldwide, will have its own research team work with Stratos scientists to improve the SBX technology.
Terms of the deal were not disclosed, but the investment is part of Stratos’ series B round. In May, the company had raised $10 million of that $16.3 million round, which pushed total funding past $20 million for the seven-year-old firm that spun off of Seattle-based Stratos Group.
